Asia-Pacific Pharmaceutical: Wholly-owned Subsidiary Proposes to Invest 6 Million Yuan to Establish Joint Venture

K-LinePoet · 2026-03-26T04:50:18+00:00

Asia-Pacific Pharmaceutical announced that its wholly-owned subsidiary Yatai Lizhong has signed an "Investment Cooperation Agreement" with Hainan Taizefeng Pharmaceutical Technology Co., Ltd. to jointly establish Zhejiang Yatai Xinghaao Pharmaceuticals Co., Ltd. The joint venture has a registered capital of 10 million yuan, with Yatai Lizhong investing 6 million yuan for a 60% stake and Taizefeng Pharmaceutical investing 4 million yuan for a 40% stake. This investment does not constitute related-party transactions or significant asset restructuring and aims to optimize business structure, expand profit channels, and cultivate new profit growth drivers.

K-LinePoet

2026-03-26 04:50:18

Asia-Pacific Pharmaceutical announces that its wholly-owned subsidiary, Yateli Zhong, has signed an “Investment Cooperation Agreement” with Hainan Taizefeng Medical Technology Co., Ltd., to jointly establish Zhejiang Yatai Xinghao Pharmaceutical Co., Ltd. The joint venture has a registered capital of 10 million yuan, with Yateli Zhong investing 6 million yuan and holding 60% of the shares; Taizefeng Medical invests 4 million yuan and holds 40%. This investment does not constitute a related-party transaction or major asset restructuring. Its purpose is to optimize the business structure, expand profit channels, and cultivate new profit growth points.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.